Download Files:
Evenamide
$142 – $2,300
Products Details
Product Description
– Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness[1][2].
Web ID
– HY-17612
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C16H26N2O2
References
– [1]Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia.|[2]Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115.
CAS Number
– 1092977-61-1
Molecular Weight
– 278.39
Compound Purity
– 98.29
SMILES
– O=C(N(C)C)CNCCC1=CC=CC(OCCCC)=C1
Clinical Information
– Phase 2
Research Area
– Neurological Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Sodium Channel
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
